CyclotriazadisulfonamideAlternative Names: CADA
Latest Information Update: 22 Aug 2007
At a glance
- Originator Nonindustrial source; Rega Institute for Medical Research; University of Nevada Reno
- Class Antivirals
- Mechanism of Action CD4 antigen inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Herpesvirus infections; HIV infections